Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (5032) 5032
Publication (234) 234
Book Review (32) 32
Book Chapter (5) 5
Conference Proceeding (3) 3
Magazine Article (3) 3
Book / eBook (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (4564) 4564
antineoplastic combined chemotherapy protocols - therapeutic use (3246) 3246
female (2953) 2953
male (2784) 2784
oncology (2723) 2723
ifosfamide - administration & dosage (2631) 2631
adult (2488) 2488
middle aged (2300) 2300
ifosfamide (1985) 1985
chemotherapy (1692) 1692
aged (1650) 1650
cisplatin - administration & dosage (1185) 1185
etoposide - administration & dosage (1181) 1181
index medicus (1178) 1178
treatment outcome (1164) 1164
adolescent (1056) 1056
ifosfamide - therapeutic use (1032) 1032
antineoplastic combined chemotherapy protocols - adverse effects (1005) 1005
cancer (992) 992
doxorubicin - administration & dosage (928) 928
combined modality therapy (909) 909
ifosfamide - adverse effects (879) 879
cisplatin (811) 811
lung neoplasms - drug therapy (710) 710
child (697) 697
prognosis (641) 641
etoposide (601) 601
survival rate (597) 597
disease-free survival (562) 562
carboplatin - administration & dosage (551) 551
drug administration schedule (547) 547
vincristine - administration & dosage (526) 526
survival analysis (524) 524
neoplasm staging (523) 523
sarcoma - drug therapy (518) 518
cyclophosphamide - administration & dosage (505) 505
retrospective studies (490) 490
doxorubicin (479) 479
therapy (476) 476
pharmacology & pharmacy (469) 469
child, preschool (465) 465
hematology (462) 462
cyclophosphamide (460) 460
antineoplastic combined chemotherapy protocols - administration & dosage (455) 455
salvage therapy (424) 424
remission induction (420) 420
sarcoma (415) 415
antineoplastic agents - therapeutic use (414) 414
chemotherapy, adjuvant (395) 395
follow-up studies (394) 394
carboplatin (385) 385
animals (376) 376
survival (367) 367
carcinoma, non-small-cell lung - drug therapy (366) 366
methotrexate - administration & dosage (345) 345
tumors (344) 344
young adult (342) 342
paclitaxel - administration & dosage (335) 335
bone neoplasms - drug therapy (333) 333
paclitaxel (333) 333
dose-response relationship, drug (332) 332
care and treatment (330) 330
trial (328) 328
phase-ii trial (327) 327
phase-ii (325) 325
mesna - administration & dosage (323) 323
antineoplastic agents, alkylating - therapeutic use (315) 315
children (312) 312
pediatrics (312) 312
surgery (308) 308
radiotherapy (294) 294
prospective studies (281) 281
medicine & public health (280) 280
neoplasm recurrence, local - drug therapy (279) 279
carcinoma (269) 269
cisplatin - adverse effects (269) 269
mesna (268) 268
cisplatin - therapeutic use (261) 261
neoplasms - drug therapy (260) 260
infant (257) 257
time factors (257) 257
soft tissue neoplasms - drug therapy (255) 255
doxorubicin - therapeutic use (252) 252
etoposide - therapeutic use (252) 252
aged, 80 and over (251) 251
etoposide - adverse effects (250) 250
combination chemotherapy (241) 241
antineoplastic agents, alkylating - administration & dosage (237) 237
testicular neoplasms - drug therapy (234) 234
vinblastine - administration & dosage (234) 234
deoxycytidine - analogs & derivatives (232) 232
obstetrics & gynecology (231) 231
osteosarcoma - drug therapy (230) 230
bleomycin - administration & dosage (227) 227
gemcitabine (227) 227
neoplasm metastasis (227) 227
high-dose chemotherapy (222) 222
toxicity (221) 221
infusions, intravenous (220) 220
risk factors (214) 214
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (4586) 4586
Japanese (159) 159
German (112) 112
French (79) 79
Chinese (37) 37
Polish (18) 18
Spanish (18) 18
Italian (11) 11
Russian (5) 5
Bulgarian (2) 2
Czech (2) 2
Hebrew (2) 2
Hungarian (2) 2
Lithuanian (2) 2
Turkish (2) 2
Danish (1) 1
Dutch (1) 1
Finnish (1) 1
Korean (1) 1
Norwegian (1) 1
Portuguese (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text ABVD versus BEACOPP for Hodgkin's Lymphoma When High-Dose Salvage Is Planned
by Viviani, Simonetta and Zinzani, Pier Luigi and Rambaldi, Alessandro and Brusamolino, Ercole and Levis, Alessandro and Bonfante, Valeria and Vitolo, Umberto and Pulsoni, Alessandro and Liberati, Anna Marina and Specchia, Giorgina and Valagussa, Pinuccia and Rossi, Andrea and Zaja, Francesco and Pogliani, Enrico M and Pregno, Patrizia and Gotti, Manuel and Gallamini, Andrea and Scalabrini, Delia Rota and Bonadonna, Gianni and Gianni, Alessandro M and Intergrp Italiano Linfomi and Grp Italiano Terapie Innovative Ne and Michelangelo Fdn and Michelangelo Foundation and Intergruppo Italiano Linfomi and Gruppo Italiano di Terapie Innovative nei Linfomi
The New England Journal of Medicine, ISSN 0028-4793, 07/2011, Volume 365, Issue 3, pp. 203 - 212
BEACOPP combination chemotherapy was compared with ABVD chemotherapy in advanced Hodgkin's disease. BEACOPP therapy was associated with higher initial rates of... 
CELL TRANSPLANT | MEDICINE, GENERAL & INTERNAL | VINORELBINE | MOPP | DISEASE | REGIMEN | IFOSFAMIDE | CHEMOTHERAPY | STANDARD | HYBRID | FERTILITY | Doxorubicin - therapeutic use | Dacarbazine - adverse effects | Dacarbazine - therapeutic use | Humans | Middle Aged | Salvage Therapy | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Vinblastine - therapeutic use | Cyclophosphamide - adverse effects | Cyclophosphamide - therapeutic use | Young Adult | Hodgkin Disease - radiotherapy | Bleomycin - therapeutic use | Vinblastine - adverse effects | Hodgkin Disease - drug therapy | Hodgkin Disease - mortality | Adult | Female | Etoposide - adverse effects | Prednisone - adverse effects | Kaplan-Meier Estimate | Proportional Hazards Models | Hematopoietic Stem Cell Transplantation | Etoposide - therapeutic use | Combined Modality Therapy | Bleomycin - adverse effects | Remission Induction | Disease-Free Survival | Procarbazine - adverse effects | Procarbazine - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Hodgkin Disease - therapy | Adolescent | Vincristine - therapeutic use | Vincristine - adverse effects | Neoplasm Staging | Doxorubicin - adverse effects | Prednisone - therapeutic use | Procarbazine | Vinblastine | Disease | Etoposide | Prednisone | Family medical history | Radiation therapy | Patients | Lymphoma | Doxorubicin | Survival | Vincristine | Studies | Hepatitis | Dacarbazine | Cyclophosphamide | Chemotherapy | Bleomycin | Tomography | Lymphomas | Hodgkin's disease
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Outcomes of patients with double-hit lymphoma who achieve first complete remission
by Landsburg, Daniel J and Mato, Anthony R and Gerson, James N and Barta, Stefan K and Falkiewicz, Marissa K and Howlett, Christina and Feldman, Tatyana and Maly, Joseph and Blum, Kristie A and Hill, Brian T and Li, Shaoying and Medeiros, L. Jeffrey and Torka, Pallawi and Hernandez-Ilizaliturri, Francisco and Lue, Jennifer K and Amengual, Jennifer E and Reddy, Nishitha M and Singavi, Arun and Fenske, Timothy S and Chavez, Julio C and Kaplan, Jason B and Behdad, Amir and Petrich, Adam M and Peace, David J and Nathan, Sunita and Bast, Martin A and Vose, Julie M and Olszewski, Adam J and Costa, Cristiana and Lansigan, Frederick and Calzada, Oscar and Cohen, Jonathon B and Rivera, Xavier and Persky, Daniel O and Cassaday, Ryan D
Journal of Clinical Oncology, ISSN 0732-183X, 07/2017, Volume 35, Issue 20, pp. 2260 - 2267
PurposePatients with double-hit lymphoma (DHL) rarely achieve long-term survival following disease relapse. Some patients with DHL undergo consolidative... 
B-CELL LYMPHOMA | IMMUNOCHEMOTHERAPY | RITUXIMAB PLUS CYCLOPHOSPHAMIDE | ONCOLOGY | RECOMMENDATIONS | PROGRESSION-FREE SURVIVAL | POOR-PROGNOSIS | MYC | IN-SITU HYBRIDIZATION | REPRODUCIBILITY | TRANSPLANTATION | Doxorubicin - therapeutic use | Recurrence | Cytarabine - therapeutic use | Humans | Lymphoma, B-Cell - therapy | Middle Aged | Male | Transplantation, Autologous | Methotrexate - therapeutic use | Lymphoma, B-Cell - genetics | Cyclophosphamide - therapeutic use | Stem Cell Transplantation | Female | Ifosfamide - therapeutic use | Etoposide - therapeutic use | Survival Rate | Remission Induction | Cytarabine - administration & dosage | Proto-Oncogene Proteins c-bcl-6 - genetics | Disease-Free Survival | Dexamethasone - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Vincristine - therapeutic use | Methotrexate - administration & dosage | Proto-Oncogene Proteins c-myc - genetics | Proto-Oncogene Proteins c-bcl-2 - genetics | Prednisone - therapeutic use | Antibodies, Monoclonal, Murine-Derived - therapeutic use | ORIGINAL REPORTS
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial
by Schöffski, Patrick, Prof and Chawla, Sant, MD and Maki, Robert G, Prof and Italiano, Antoine, MD and Gelderblom, Hans, Prof and Choy, Edwin, MD and Grignani, Giovanni, MD and Camargo, Veridiana, MD and Bauer, Sebastian, MD and Rha, Sun Young, MD and Blay, Jean-Yves, Prof and Hohenberger, Peter, MD and D'Adamo, David, MD and Guo, Matthew, PhD and Chmielowski, Bartosz, MD and Le Cesne, Axel, MD and Demetri, George D, Prof and Patel, Shreyaskumar R, Prof
Lancet, The, ISSN 0140-6736, 2016, Volume 387, Issue 10028, pp. 1629 - 1637
Summary Background A non-randomised, phase 2 study showed activity and tolerability of eribulin in advanced or metastatic soft-tissue sarcoma. In this phase 3... 
Internal Medicine | MESYLATE | MEDICINE, GENERAL & INTERNAL | PAZOPANIB | ANTHRACYCLINE | DOUBLE-BLIND | IFOSFAMIDE | DOCETAXEL | SOFT-TISSUE SARCOMA | GEMCITABINE | CHEMOTHERAPY | Dacarbazine - adverse effects | Dacarbazine - therapeutic use | Humans | Middle Aged | Soft Tissue Neoplasms - drug therapy | Male | Antineoplastic Agents - therapeutic use | Furans - adverse effects | Furans - therapeutic use | Young Adult | Neoplasm Grading | Antineoplastic Agents - adverse effects | Aged, 80 and over | Adult | Female | Ketones - therapeutic use | Ketones - adverse effects | Leiomyosarcoma - pathology | Liposarcoma - drug therapy | Liposarcoma - pathology | Treatment Outcome | Antineoplastic Agents, Alkylating - therapeutic use | Leiomyosarcoma - secondary | Liposarcoma - secondary | Survival Analysis | Leiomyosarcoma - drug therapy | Aged | Antineoplastic Agents, Alkylating - adverse effects | Medical colleges | Care and treatment | Hospitals | Metastasis | Sarcoma | France | Leiomyosarcoma | Chemotherapy | Clinical trials | Cytotoxicity | Cancer therapies | Clinical outcomes | Pharmaceuticals | Cancer | Life Sciences
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text How I treat Burkitt lymphoma in adults
by Jacobson, Caron and La Casce, Ann
Blood, ISSN 0006-4971, 11/2014, Volume 124, Issue 19, pp. 2913 - 2920
4 Burkitt lymphoma (BL) is an aggressive B-cell non-Hodgkin lymphoma that is almost uniformly associated with translocations involving the gene for MYC on... 
LEUKEMIA GROUP-B | UNITED-STATES | INTENSIVE CHEMOTHERAPY | CODOX-M/IVAC | GENE | NON-HODGKINS-LYMPHOMAS | C-MYC | GERMINAL CENTER | STEM-CELL TRANSPLANTATION | HEMATOLOGY | EPSTEIN-BARR-VIRUS | Doxorubicin - therapeutic use | Nasopharyngeal Neoplasms - genetics | Translocation, Genetic | Ifosfamide - therapeutic use | Prognosis | Cytarabine - therapeutic use | Humans | Etoposide - therapeutic use | Male | Burkitt Lymphoma - diagnosis | Methotrexate - therapeutic use | Cyclophosphamide - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Vincristine - therapeutic use | Burkitt Lymphoma - genetics | Adult | Nasopharyngeal Neoplasms - drug therapy | Nasopharyngeal Neoplasms - diagnosis | Prednisone - therapeutic use | Burkitt Lymphoma - drug therapy
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Impact of oncogene rearrangement patterns on outcomes in patients with double‐hit non‐Hodgkin lymphoma
by Landsburg, Daniel J and Petrich, Adam M and Abramson, Jeremy S and Sohani, Aliyah R and Press, Oliver and Cassaday, Ryan and Chavez, Julio C and Song, Kevin and Zelenetz, Andrew D and Gandhi, Mitul and Shah, Namrata and Fenske, Timothy S and Jaso, Jesse and Medeiros, L. Jeffrey and Yang, David T and Nabhan, Chadi
Cancer, ISSN 0008-543X, 02/2016, Volume 122, Issue 4, pp. 559 - 564
BACKGROUND Double‐hit lymphomas (DHLs) are collectively defined as B‐cell non‐Hodgkin lymphomas harboring rearrangements of MYC as well as B‐cell lymphoma 2... 
BCL6 (B‐cell lymphoma 6) | non‐Hodgkin lymphoma | gene rearrangement | BCL2 (B‐cell lymphoma 2) | MYC | BCL6 (B-cell lymphoma 6) | non-Hodgkin lymphoma | BCL2 (B-cell lymphoma 2) | RITUXIMAB PLUS CYCLOPHOSPHAMIDE | TRANSLOCATIONS | IN-VIVO EFFICACY | DOXORUBICIN | B-CELL LYMPHOMA | PREDNISONE | BCL6 | ONCOLOGY | VINCRISTINE | EXPRESSION | Doxorubicin - therapeutic use | Prognosis | Cytarabine - therapeutic use | Humans | Middle Aged | Male | Methotrexate - therapeutic use | Bone Marrow Neoplasms - genetics | Lymphoma, B-Cell - genetics | Cyclophosphamide - therapeutic use | Lymphoma, Non-Hodgkin - pathology | Burkitt Lymphoma - pathology | Burkitt Lymphoma - genetics | Female | Burkitt Lymphoma - drug therapy | Databases, Factual | Lymphoma, B-Cell - drug therapy | Lymphoma, Non-Hodgkin - drug therapy | Ifosfamide - therapeutic use | Lymphoma, Large B-Cell, Diffuse - drug therapy | Lymphoma, Large B-Cell, Diffuse - pathology | Central Nervous System Neoplasms - genetics | Etoposide - therapeutic use | Survival Rate | Germinal Center - pathology | Lymphoma, Non-Hodgkin - genetics | DNA-Binding Proteins - genetics | Genes, bcl-2 - genetics | Rituximab - administration & dosage | Central Nervous System Neoplasms - pathology | Dexamethasone - therapeutic use | Bone Marrow Neoplasms - pathology | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Gene Rearrangement | Genes, myc - genetics | Lymphoma, B-Cell - pathology | Vincristine - therapeutic use | Bone Marrow Neoplasms - drug therapy | Central Nervous System Neoplasms - drug therapy | Lymphoma, Large B-Cell, Diffuse - genetics | Prednisone - therapeutic use | Cohort Studies | Proto-Oncogene Proteins c-bcl-6 | Care and treatment | Chemotherapy | Usage | Non-Hodgkin's lymphomas | Diagnosis | Research | Oncogenes | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Nonmetastatic Ewing family tumors: High-dose chemotherapy with stem cell rescue in poor responder patients. results of the Italian Sarcoma Group/Scandinavian Sarcoma Group III protocol
by Ferrari, S and Hall, K. Sundby and Luksch, R and Tienghi, A and Wiebe, T and Fagioli, F and Alvegard, T.A and del Prever, A. Brach and Tamburini, A and Alberghini, M and Gandola, L and Mercuri, M and Capanna, R and Mapelli, S and Prete, A and Carli, M and Picci, P and Barbieri, E and Bacci, G and Smeland, S and Cancerepidemiologi and Lund University and Sektion V and Cancer Epidemiology and Lunds universitet and Division V
Annals of Oncology, ISSN 0923-7534, 2011, Volume 22, Issue 5, pp. 1221 - 1227
Background: High-dose chemotherapy (HDT) was added to conventional chemotherapy in Ewing sarcoma family tumor (EFT) patients, poor responders (PRs) to... 
Chemotherapy-induced necrosis | Ewing sarcoma | High-dose chemotherapy | TOTAL-BODY IRRADIATION | STANDARD CHEMOTHERAPY | PROGNOSTIC-FACTORS | BONE-MARROW-TRANSPLANTATION | IFOSFAMIDE | ETOPOSIDE | chemotherapy-induced necrosis | ONCOLOGY | FRENCH-SOCIETY | CONSOLIDATION THERAPY | MULTIMODAL THERAPY | PEDIATRIC-ONCOLOGY | high-dose chemotherapy | Myeloablative Agonists - therapeutic use | Bone Neoplasms - mortality | Doxorubicin - therapeutic use | Bone Neoplasms - therapy | Sarcoma, Ewing - therapy | Humans | Child, Preschool | Male | Sarcoma, Ewing - mortality | Melphalan - therapeutic use | Cyclophosphamide - therapeutic use | Young Adult | Dactinomycin - therapeutic use | Adult | Female | Child | Ifosfamide - therapeutic use | Busulfan - therapeutic use | Kaplan-Meier Estimate | Etoposide - therapeutic use | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adolescent | Vincristine - therapeutic use | Peripheral Blood Stem Cell Transplantation | Index Medicus | Clinical Medicine | Medical and Health Sciences | Medicin och hälsovetenskap | Klinisk medicin | Cancer and Oncology | Cancer och onkologi
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Early treatment intensification with R-ICE and 90Y-ibritumomab tiuxetan (Zevalin)-BEAM stem cell transplantation in patients with high-risk diffuse large B-cell lymphoma patients and positive interim PET after 4 cycles of R-CHOP-14
by Hertzberg, Mark and Gandhi, Maher K and Trotman, Judith and Butcher, Belinda and Taper, John and Johnston, Amanda and Gill, Devinder and Ho, Shir-Jing and Cull, Gavin and Fay, Keith and Chong, Geoff and Grigg, Andrew and Lewis, Ian D and Milliken, Sam and Renwick, William and Hahn, Uwe and Filshie, Robin and Kannourakis, George and Watson, Anne-Marie and Warburton, Pauline and Wirth, Andrew and Seymour, John F and Hofman, Michael S and Hicks, Rodney J and ALLG and Australasian Leukaemia Lymphoma Group (ALLG)
Haematologica, ISSN 0390-6078, 2017, Volume 102, Issue 2, pp. 356 - 363
In the treatment of diffuse large B-cell lymphoma a persistently positive [18F]fluorodeoxyglucose positron emission tomography (PET) scan typically carries a... 
FDG-PET | PHASE-II TRIAL | POSITRON-EMISSION-TOMOGRAPHY | INTERNATIONAL PROGNOSTIC INDEX | RESPONSE ASSESSMENT | NON-HODGKINS-LYMPHOMA | AGGRESSIVE LYMPHOMA | HIGH-DOSE CHEMOTHERAPY | Y-90 IBRITUMOMAB TIUXETAN | HEMATOLOGY | SUV-BASED ASSESSMENT | Doxorubicin - therapeutic use | Cytarabine - therapeutic use | Humans | Middle Aged | Podophyllotoxin - therapeutic use | Male | Melphalan - therapeutic use | Cyclophosphamide - therapeutic use | Young Adult | Carmustine - therapeutic use | Lymphoma, Large B-Cell, Diffuse - diagnostic imaging | Lymphoma, Large B-Cell, Diffuse - therapy | Adult | Female | Carboplatin - administration & dosage | Etoposide - administration & dosage | Treatment Outcome | Positron-Emission Tomography - methods | Lymphoma, Large B-Cell, Diffuse - mortality | Rituximab - administration & dosage | Retreatment | Ifosfamide - administration & dosage | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Vincristine - therapeutic use | Fluorodeoxyglucose F18 | Aged | Prednisone - therapeutic use | Antibodies, Monoclonal, Murine-Derived - therapeutic use
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial
by Tap, William D, Dr and Jones, Robin L, MD and Van Tine, Brian A, MD and Chmielowski, Bartosz, MD and Elias, Anthony D, Prof and Adkins, Douglas, Prof and Agulnik, Mark, MD and Cooney, Matthew M, MD and Livingston, Michael B, MD and Pennock, Gregory, MD and Hameed, Meera R, MD and Shah, Gaurav D, MD and Qin, Amy, PhD and Shahir, Ashwin, MD and Cronier, Damien M, PhD and Ilaria, Robert, MD and Conti, Ilaria, MD and Cosaert, Jan, MD and Schwartz, Gary K, Prof
Lancet, The, ISSN 0140-6736, 2016, Volume 388, Issue 10043, pp. 488 - 497
Summary Background Treatment with doxorubicin is a present standard of care for patients with metastatic soft-tissue sarcoma and median overall survival for... 
Internal Medicine | PATHWAYS | 1ST-LINE TREATMENT | PLUS IFOSFAMIDE | MEDICINE, GENERAL & INTERNAL | PDGF | DOSE DOXORUBICIN | EUROPEAN-ORGANIZATION | GROWTH-FACTOR | INTENSIFIED DOXORUBICIN | III TRIAL | STANDARD | Doxorubicin - therapeutic use | Drug Administration Schedule | United States | Humans | Middle Aged | Kaplan-Meier Estimate | Male | Treatment Outcome | Sarcoma - drug therapy | Patient Selection | Antibiotics, Antineoplastic - administration & dosage | Disease-Free Survival | Antibiotics, Antineoplastic - therapeutic use | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged, 80 and over | Adult | Female | Aged | Doxorubicin - administration & dosage | Medical colleges | Care and treatment | Anthracyclines | Chemotherapy | Hospitals | Sarcoma | Monoclonal antibodies | Product development | Metastasis | Pharmaceutical industry | Cancer | Clinical trials | Clinical outcomes | Tumors
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Aprepitant and fosaprepitant drug interactions: a systematic review
by Patel, Priya and Leeder, J. Steven and Piquette‐Miller, Micheline and Dupuis, L. Lee
British Journal of Clinical Pharmacology, ISSN 0306-5251, 10/2017, Volume 83, Issue 10, pp. 2148 - 2162
Aims Aprepitant and fosaprepitant, commonly used for the prevention of chemotherapy‐induced nausea and vomiting, alter cytochrome P450 activity. This... 
aprepitant | drug–drug interactions | fosaprepitant | METHYLENE-BLUE | CHEMOTHERAPY-INDUCED NAUSEA | SITE ADVERSE EVENTS | CYTOCHROME-P450 3A4 | IFOSFAMIDE | drug-drug interactions | CANCER-PATIENTS | CONCISE GUIDE | PHARMACOKINETICS | PHARMACOLOGY & PHARMACY | INDUCED NEUROTOXICITY | RECEPTOR ANTAGONIST APREPITANT | Cytochrome P-450 CYP3A Inhibitors - pharmacology | Nausea - chemically induced | Humans | Antineoplastic Agents - therapeutic use | Drug Interactions | Cytochrome P-450 CYP2C9 Inducers - pharmacology | Antiemetics - therapeutic use | Antineoplastic Agents - pharmacology | Vomiting - prevention & control | Morpholines - therapeutic use | Quetiapine Fumarate - pharmacology | Aprepitant | Oxycodone - therapeutic use | Oxycodone - pharmacology | Injection Site Reaction - etiology | Serotonin Uptake Inhibitors - therapeutic use | Morpholines - pharmacology | Quetiapine Fumarate - therapeutic use | Nausea - prevention & control | Vomiting - chemically induced | Ethanol - pharmacology | Serotonin and Noradrenaline Reuptake Inhibitors - pharmacology | Cytochrome P-450 CYP2C9 Inducers - therapeutic use | Serotonin and Noradrenaline Reuptake Inhibitors - therapeutic use | Cytochrome P-450 CYP3A Inhibitors - therapeutic use | Antiemetics - pharmacology | Complications and side effects | Anthracyclines | Chemotherapy | Corticosteroids | Gastrointestinal agents | Drug interactions | Nausea | Cancer | Index Medicus | Systematic Review and Meta–Analysis
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text An oncogenic NTRK fusion in a patient with soft-tissue sarcoma with response to the tropomyosin-related kinase inhibitor LOXO-101
by Doebele, Robert C and Davis, Lara E and Vaishnavi, Aria and Le, Anh T and Estrada-Bernal, Adriana and Keysar, Stephen and Jimeno, Antonio and Varella-Garcia, Marileila and Aisner, Dara L and Li, Yali and Stephens, Philip J and Morosini, Deborah and Tuch, Brian B and Fernandes, Michele and Nanda, Nisha and Low, Jennifer A
Cancer Discovery, ISSN 2159-8274, 10/2015, Volume 5, Issue 10, pp. 1049 - 1057
Oncogenic TRK fusions induce cancer cell proliferation and engage critical cancer-related downstream signaling pathways. These TRK fusions occur rarely, but in... 
CELL LUNG-CANCER | THERAPY | ONCOLOGY | LANDSCAPE | DOXORUBICIN | INFLAMMATORY MYOFIBROBLASTIC TUMOR | CRIZOTINIB | NGF | IFOSFAMIDE | STANDARD | Oncogene Proteins - genetics | Pyrazoles - therapeutic use | Humans | Tomography, X-Ray Computed | Antineoplastic Agents - therapeutic use | Dose-Response Relationship, Drug | Cell Transformation, Neoplastic - genetics | Adult | Female | Antineoplastic Agents - pharmacology | Sarcoma - diagnosis | Sarcoma - genetics | Pyrazoles - pharmacology | Treatment Outcome | Pyrimidines - pharmacology | Sarcoma - drug therapy | Oncogene Proteins - antagonists & inhibitors | Oncogene Proteins, Fusion - genetics | Protein Kinase Inhibitors - therapeutic use | Pyrimidines - therapeutic use | Lamin Type A - genetics | Cell Line, Tumor | Oncogene Proteins, Fusion - antagonists & inhibitors | Cell Proliferation - drug effects | Protein Kinase Inhibitors - pharmacology | Neoplasm Staging
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Primary Disseminated Multifocal Ewing Sarcoma: Results of the Euro-EWING 99 Trial
by Ruth Ladenstein and Ulrike Pötschger and Marie Cécile Le Deley and Jeremy Whelan and Michael Paulussen and Odile Oberlin and Henk van den Berg and Uta Dirksen and Lars Hjorth and Jean Michon and Ian Lewis and Alan Craft and Heribert Jürgens
Journal of Clinical Oncology, ISSN 0732-183X, 07/2010, Volume 28, Issue 20, pp. 3284 - 3291
Purpose To improve the poor prognosis of patients with primary disseminated multifocal Ewing sarcomas (PDMES) with a dose-intense treatment concept. Patients... 
TOTAL-BODY IRRADIATION | YOUNG-ADULTS | STEM-CELL RESCUE | PRIMITIVE NEUROECTODERMAL TUMORS | PROGNOSTIC-FACTORS | ONCOLOGY | SURVIVAL ANALYSIS | SHORT-TERM CHEMOTHERAPY | BONE-MARROW | PEDIATRIC-PATIENTS | HIGH-DOSE CHEMOTHERAPY | Ifosfamide - therapeutic use | Prognosis | Drug Administration Schedule | Humans | Middle Aged | Risk Factors | Sarcoma, Ewing - pathology | Child, Preschool | Etoposide - administration & dosage | Infant | Combined Modality Therapy | Sarcoma, Ewing - mortality | Sarcoma, Ewing - drug therapy | Dactinomycin - therapeutic use | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adolescent | Vincristine - therapeutic use | Adult | Child
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Randomized Multicenter and Stratified Phase II Study of Gemcitabine Alone Versus Gemcitabine and Docetaxel in Patients with Metastatic or Relapsed Leiomyosarcomas: A Fédération Nationale des Centres de Lutte Contre le Cancer (FNCLCC) French Sarcoma Group Study (TAXOGEM study)
by Pautier, Patricia and Floquet, Anne and Penel, Nicolas and Piperno‐Neumann, Sophie and Isambert, Nicolas and Rey, Annie and Bompas, Emmanuelle and Cioffi, Angela and Delcambre, Corinne and Cupissol, Didier and Collin, Françoise and Blay, Jean‐Yves and Jimenez, Marta and Duffaud, Florence
The Oncologist, ISSN 1083-7159, 09/2012, Volume 17, Issue 9, pp. 1213 - 1220
Background. This study aimed to evaluate the efficacy and toxicity of single‐agent gemcitabine versus gemcitabine plus docetaxel as second‐line therapy in... 
Chemotherapy | Gemcitabine | Leiomyosarcoma | Docetaxel | SOFT-TISSUE SARCOMAS | GYNECOLOGIC-ONCOLOGY-GROUP | PROGNOSTIC-FACTORS | EUROPEAN ORGANIZATION | DOXORUBICIN | 2ND-LINE CHEMOTHERAPY | UTERINE SARCOMAS | IFOSFAMIDE | TRIAL | ONCOLOGY | DOSE-RATE | Recombinant Proteins - therapeutic use | France - epidemiology | Leiomyosarcoma - pathology | Uterine Neoplasms - pathology | Humans | Middle Aged | Neoplasm Recurrence, Local | Male | Granulocyte Colony-Stimulating Factor - therapeutic use | Dose-Response Relationship, Drug | Disease-Free Survival | Taxoids - therapeutic use | Deoxycytidine - therapeutic use | Neoplasm Metastasis | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Uterine Neoplasms - drug therapy | Adult | Female | Leiomyosarcoma - drug therapy | Aged | Deoxycytidine - analogs & derivatives | Sarcomas
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights